Independent 3rd Party Peer ReviewSo management advised the markets that the phase 2 independent third party peer review would be released before the end of 1H/2023 which was June 30, We are now fast approaching Q4/2023.
What's up with that? Are there supply chain issues with computer ink?
We have one analyst who is waiting on this report and as each day goes by we continue to hit new 52 week lows.
In November 2020 we hit $5.05 and we currently trade around $1.50, down 75%. We have less risk, safe higher dosage study, FDA approved new phase 2 approved for AKI trial yet here we are below $100M market cap.
Something is not adding up here. CIBC and Scotiabank have been pounding this stock to new 52 week lows for over a year now, yet all is well with management. We have zero let me repeat 0% institutional ownership in this company yet many of it's similar staged peers have 20-35% Institutional ownership and guess what they have market caps of $1B or higher.
This management team for whatever reason has failed to attrack institutional money and is simply terrible at communicating to the markets.